Drug Trial Radar · NCT02638103
Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine
Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,890
Actual
Start
Feb 26, 2016
Primary completion
Jun 6, 2018
Study completion Dec 8, 2018
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Dec 22, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous (SC) administration of TEV-48125 in adult participants with chronic migraine (CM) or episodic migraine (EM). Participants with CM or EM who complete the pivotal efficacy studies of TEV-48125 (TV48125-CNS-30049 \[NCT02621931\] and TV48125-CNS-30050 \[NCT02629861\]) and agree to participate in this study; and new participants meeting eligibility criteria (not rolling over from pivotal studies), will be enrolled in this study.
Conditions
- Migraine
Interventions
FremanezumabDrug
Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
PlaceboDrug
Placebo matching to fremanezumab will be administered as per schedule specified in the respective arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: Baseline (Day 0) up to follow-up visit (Day 533)
- Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry ResultsTime frame: Baseline (Day 0) up to end of treatment (EOT) visit (Day 336)
- Number of Participants With Potentially Clinically Significant Abnormal Hematology ResultsTime frame: Baseline (Day 0) up to EOT visit (Day 336)
- Number of Participants With Potentially Clinically Significant Abnormal Urinalysis Laboratory Tests ResultsTime frame: Baseline (Day 0) up to EOT visit (Day 336)
- Number of Participants With Potentially Clinically Significant Abnormal Vital Signs ValuesTime frame: Baseline (Day 0) up to EOT visit (Day 336)
- Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) ParametersTime frame: Baseline (Day 0), endpoint (Day 336)
- Number of Participants With Shift From Baseline to Endpoint in Coagulation Laboratory Test ResultsTime frame: Baseline (Day 0), endpoint (Day 336)
- Number of Participants With Injection Site ReactionsTime frame: Baseline (Day -28 to Day -1), Month 12
- Number of Participants With Suicidal Ideation and Suicidal Behavior as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS)Time frame: Baseline (Day -28 to Day -1), Month 12
Locations
139 sites in 9 countries. Site status is shown where the registry gives one.
Teva Investigational Site 13628
Birmingham, Alabama
Teva Investigational Site 13577
Birmingham, Alabama
Teva Investigational Site 13606
Phoenix, Arizona
Teva Investigational Site 13579
Phoenix, Arizona
Teva Investigational Site 13602
Little Rock, Arkansas
Teva Investigational Site 13568
Encino, California
Teva Investigational Site 13546
Fullerton, California
Teva Investigational Site 13540
Long Beach, California
Teva Investigational Site 13632
Redlands, California
Teva Investigational Site 13571
Redondo Beach, California
Teva Investigational Site 13573
San Diego, California
Teva Investigational Site 13538
Santa Monica, California
Teva Investigational Site 13594
Santa Rosa, California
Teva Investigational Site 13595
Walnut Creek, California
Teva Investigational Site 13629
Aurora, Colorado
Teva Investigational Site 13557
Boulder, Colorado
Teva Investigational Site 13593
Colorado Springs, Colorado
Teva Investigational Site 13633
Denver, Colorado
Teva Investigational Site 13612
Denver, Colorado
Teva Investigational Site 13631
Englewood, Colorado
Teva Investigational Site 13563
East Hartford, Connecticut
Teva Investigational Site 13550
Stamford, Connecticut
Teva Investigational Site 13635
Bradenton, Florida
Teva Investigational Site 13597
Gainesville, Florida
Teva Investigational Site 13607
Hialeah, Florida
Teva Investigational Site 13559
Jacksonville, Florida
Teva Investigational Site 13584
Ocala, Florida
Teva Investigational Site 13587
Orlando, Florida
Teva Investigational Site 13567
Palm Beach Gardens, Florida
Teva Investigational Site 13553
Pembroke Pines, Florida
Teva Investigational Site 13616
Pinellas Park, Florida
Teva Investigational Site 13620
Atlanta, Georgia
Teva Investigational Site 13537
Atlanta, Georgia
Teva Investigational Site 13604
Boise, Idaho
Teva Investigational Site 13585
Chicago, Illinois
Teva Investigational Site 13621
Chicago, Illinois
Teva Investigational Site 13627
Evanston, Illinois
Teva Investigational Site 13596
Indianapolis, Indiana
Teva Investigational Site 13617
Wichita, Kansas
Teva Investigational Site 13598
Wichita, Kansas
Showing 40 of 139 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.